Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Intangibles (2016 - 2025)

Historic Intangibles for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $499.8 million.

  • Ani Pharmaceuticals' Intangibles fell 1228.59% to $499.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $499.8 million, marking a year-over-year decrease of 1228.59%. This contributed to the annual value of $541.8 million for FY2024, which is 15923.96% up from last year.
  • Ani Pharmaceuticals' Intangibles amounted to $499.8 million in Q3 2025, which was down 1228.59% from $520.3 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Intangibles' 5-year high stood at $569.8 million during Q3 2024, with a 5-year trough of $170.1 million in Q3 2021.
  • In the last 5 years, Ani Pharmaceuticals' Intangibles had a median value of $499.8 million in 2025 and averaged $368.7 million.
  • Its Intangibles has fluctuated over the past 5 years, first skyrocketed by 19827.61% in 2022, then plummeted by 6136.99% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Intangibles stood at $500.5 million in 2021, then plummeted by 49.72% to $251.6 million in 2022, then dropped by 16.94% to $209.0 million in 2023, then surged by 159.24% to $541.8 million in 2024, then decreased by 7.75% to $499.8 million in 2025.
  • Its Intangibles stands at $499.8 million for Q3 2025, versus $520.3 million for Q2 2025 and $538.5 million for Q1 2025.